Loading...
XSHE
300759
Market cap9.66bUSD
Oct 09, Last price  
43.11CNY
1D
-1.46%
1Q
27.02%
IPO
255.40%
Name

Pharmaron Beijing Co Ltd

Chart & performance

D1W1MN
XSHE:300759 chart
P/E
38.28
P/S
4.52
EPS
1.13
Div yield, %
0.46%
Shrs. gr., 5y
-0.15%
Rev. gr., 5y
22.39%
Revenues
14.10b
+14.82%
790,440,0471,128,037,5581,634,238,6802,294,118,0662,908,123,0333,757,160,0865,133,596,7587,443,769,72410,266,288,17911,537,996,31412,275,774,87514,095,078,734
Net income
1.66b
-7.22%
20,995,24073,846,442176,911,924230,857,087339,224,479547,191,4861,172,382,3871,661,028,5671,374,604,2241,601,096,0331,793,350,8141,663,898,879
CFO
3.22b
+25.01%
12,134,600216,939,062235,767,733552,215,324737,258,351938,586,3211,648,609,9572,058,043,8302,142,816,4162,753,538,9342,576,656,3973,221,047,215
Dividend
Jul 07, 20260.2 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.

Related entities

Subsidiaries
Pharmaron (Hong Kong) International Limited

Key people

Hua Yang
Chief Scientific Officer · since 2016
Boliang Lou
Executive Chairman of the Board, Chief Executive Officer · since 2016
Xiaoqiang Lou
President, Chief Operating Officer, Executive Director · since 2023
Bei Zheng
Executive Vice President, Executive Director · since 2016
Shing Chung Li
Chief Financial Officer, Secretary of the Board, Employee Representative Director · since 2025
Non-Executive Director · since 2016
Xuan Wan
Non-Executive Director · since 2025
Lihua Li
Independent Non-Executive Director · since 2022
King Fung Tsang
Independent Non-Executive Director · since 2025
Jian Yu
Independent Non-Executive Director · since 2020
IPO date
Jan 28, 2019
Employees
19,733
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
泰河路6号1幢八层
经济技术开发区
北京市, BJ 100176
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT